​
​

Salarius Pharmaceuticals (SLRX) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChart

Salarius Pharmaceuticals Revenue Highlights

00

Main Segment (Y)

Grant, Castration-Resistant Prostate Study

Main Geography (Y)

Grant, Castration-Resistant Prostate Study

Salarius Pharmaceuticals Revenue by Period

Salarius Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31--100.00%
2021-12-31$1.84M-64.84%
2020-12-31$5.23M51.03%
2019-12-31$3.47M313.49%
2018-12-31$838.00K-34.27%
2017-12-31$1.27M26.11%
2016-12-31$1.01M100.00%
2015-12-31--

Salarius Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Salarius Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$17.89K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31--100.00%
2021-12-31$-1.84M100.00%
2021-09-30--100.00%
2021-06-30$571.39K-54.97%
2021-03-31$1.27M-14.21%
2020-12-31$1.48M7.31%
2020-09-30$1.38M10.85%
2020-06-30$1.24M9.75%
2020-03-31$1.13M9.06%
2019-12-31$1.04M18.71%
2019-09-30$874.95K431.22%
2019-06-30$164.71K56.90%
2019-03-31$104.98K-35.60%
2018-12-31$163.00K-35.06%
2018-09-30$250.99K2.24%
2018-06-30$245.50K37.47%
2018-03-31$178.58K-36.90%
2017-12-31$283.00K-31.58%
2017-09-30$413.60K23.27%
2017-06-30$335.52K38.33%
2017-03-31$242.55K-18.88%
2016-12-31$299.00K-50.09%
2016-09-30$599.07K431.64%
2016-06-30$112.69K100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30--

Salarius Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Salarius Pharmaceuticals Revenue Breakdown

Salarius Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 20Dec 18
Grant, Castration-Resistant Prostate Study$2.60M-
Product and Service, Other-$11.63K
Product-$826.51K

Salarius Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Grant, Castration-Resistant Prostate Study (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Mar 21Sep 20Jun 20Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
Grant$100.00K$100.00K---------
Grant, Castration-Resistant Prostate Study--$2.60M$2.60M$2.60M------
Product-----$163.07K$104.22K$161.56K$247.28K$241.42K-
Product and Service, Other-----$1.63K$757.00$1.51K$3.71K$4.09K-
Consumer Operations----------$178.58K
Drug Development-----------

Salarius Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Grant (100.00%).

Salarius Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 18
Grant, Castration-Resistant Prostate Study$2.60M-
Product and Service, Other-$11.63K
Product-$826.51K

Salarius Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: Grant, Castration-Resistant Prostate Study (100.00%).

Quarterly Revenue by Country

CountryMar 21Sep 20Jun 20Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
Grant, Castration-Resistant Prostate Study$2.60M$2.60M$2.60M------
Product and Service, Other---$1.63K$757.00$1.51K$3.71K$4.09K-
Product---$163.07K$104.22K$161.56K$247.28K$241.42K-
Drug Development---------
Consumer Operations--------$178.58K

Salarius Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 21: Grant, Castration-Resistant Prostate Study (100.00%).

Salarius Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
PIRSPieris Pharmaceuticals$42.81M-
MREOMereo BioPharma Group$10.00M-
AFMDAffimed$8.28M$155.00K
FRTXFresh Tracks Therapeutics$8.01M-
HSTOHistogen$3.77M$5.00K
SABSSAB Biotherapeutics$2.24M$263.14K
NTRBNutriband$2.09M$442.83K
VCNXVaccinex$570.00K$52.00K
MGTADianthus Therapeutics$314.00K$72.00K
CRVSCorvus Pharmaceuticals--
ALRNAileron Therapeutics--
AKTXAkari Therapeutics--
FWBIEntero Therapeutics--
GOVXGeoVax Labs-$300.68K
AXLAAxcella Health--
ARTLArtelo Biosciences--
SLRXSalarius Pharmaceuticals--

SLRX Revenue FAQ

What is Salarius Pharmaceuticals’s yearly revenue?

Salarius Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. SLRX's yearly revenue for 2021 was $1.84M, representing a decrease of -64.84% compared to 2020.

What is Salarius Pharmaceuticals’s quarterly revenue?

Salarius Pharmaceuticals's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). SLRX's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Salarius Pharmaceuticals’s revenue growth rate?

Salarius Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.

What are Salarius Pharmaceuticals’s revenue streams?

Salarius Pharmaceuticals's revenue streams in c 20 are Grant, Castration-Resistant Prostate Study

What is Salarius Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 20, the largest source of revenue of Salarius Pharmaceuticals was Grant, Castration-Resistant Prostate Study. This segment made a revenue of $2.6M, representing 100.00% of the company's total revenue.